<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:department>Clinical and Experimental Medicine</gtr:department><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/82B77BB2-623B-436C-BE2D-2471BECE59FA"><gtr:id>82B77BB2-623B-436C-BE2D-2471BECE59FA</gtr:id><gtr:firstName>Nicholas</gtr:firstName><gtr:surname>Barnes</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/547E5B82-A001-4F98-AD4E-851B5DA0D89B"><gtr:id>547E5B82-A001-4F98-AD4E-851B5DA0D89B</gtr:id><gtr:firstName>Kate</gtr:firstName><gtr:surname>Bishop</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/90300D17-7BE0-4E54-B57F-4F4569547B87"><gtr:id>90300D17-7BE0-4E54-B57F-4F4569547B87</gtr:id><gtr:firstName>Paul</gtr:firstName><gtr:surname>Stewart</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/F394EA3E-4431-4AB4-A300-D3CA4F41857C"><gtr:id>F394EA3E-4431-4AB4-A300-D3CA4F41857C</gtr:id><gtr:firstName>Lawrence</gtr:firstName><gtr:otherNames>Sterling</gtr:otherNames><gtr:surname>Young</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0801681"><gtr:id>DDEA584E-C9A9-4967-B225-263D11EBD0F1</gtr:id><gtr:title>DPFS Resource Request (University of Birmingham)</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0801681</gtr:grantReference><gtr:abstractText>Medical research in the UK aims to find new ways of treating and diagnosing people with disease. It is important that when new medical innovations are made, steps are taken to ensure that this knowledge is exploited to its full potential and is able to make the transition from the laboratory into patient healthcare application. This proposal asks for resource to support the management of a portfolio of such innovations within the University of Birmingham, currently at an early stage of development, through to a stage where they can receive further investment and be effectively translated into new healthcare opportunities.</gtr:abstractText><gtr:technicalSummary>This project focuses on providing key support to nine commercialisation cases, which have been identified from the College IP portfolio, prior to future application for DPFS funding. A Technology Transfer Officer is requested to provide dedicated project management/development support and expertise to advance DPFS projects across the College?s portfolio of activity. It is also proposed that a flexible consultancy approach is employed to buy in external subject/sector/commercial expertise to ensure that innovative and commercially and/or health service relevant approaches are used to achieve successful exploitation and application of the new innovations arising from the College. This approach will provide the necessary resource and expertise to ensure proposals are developed which are commercially focused and have clearly defined and achievable translational objectives and endpoints. The new resource will work with and complement existing Technology Transfer support available within the College and across the University of Birmingham, to provide seamless support for Translational research.</gtr:technicalSummary><gtr:fund><gtr:end>2012-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2009-02-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>224832</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Workshops  and information events</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>5B91090B-4521-4EB9-837E-14CE4A9BE699</gtr:id><gtr:impact>Internal staff have attended an annual Business Ideas competition to learn more about commercialisation and the funding available

Increased awareness of the MRC DPFS scheme</gtr:impact><gtr:outcomeId>D1491B2CD2F</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2009,2010</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>99242</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>FPD1</gtr:description><gtr:end>2010-11-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>14A3D839-F9C5-42D2-950D-5473A751F41A</gtr:id><gtr:outcomeId>Sov3VisVcNS0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2009-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>750000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Developmental Clinical Study</gtr:description><gtr:end>2013-06-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>00FFA50E-B3D9-44A2-A437-421F34AAE101</gtr:id><gtr:outcomeId>trXHknsG6Mj0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>The combination of two tests to deliver an improved test for alzheimer's</gtr:description><gtr:grantRef>G0801681</gtr:grantRef><gtr:id>74503E5A-A859-493B-8DB9-47A81CFE389A</gtr:id><gtr:impact>None</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>Fe1SXMQAbhx</gtr:outcomeId><gtr:patentId>WO2011007155</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>A screening method for alzheimer's</gtr:title><gtr:yearProtectionGranted>2009</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>A method of diagnosing or determining the degree of an arterial aneurysm, especially an abdominal aortic aneurysm, which comprises determining the presence or level of interleukin-1a (IL-1aa) in a serum or plasma sample.</gtr:description><gtr:grantRef>G0801681</gtr:grantRef><gtr:id>3E385FB4-4F05-4D92-9D43-029DE6356C00</gtr:id><gtr:impact>Discussion with industry experts to identify new funding opportunities and develop towards these, including MRC DPFS.</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>EnbxR2zALan</gtr:outcomeId><gtr:patentId>WO2011141746</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Biomarker for arterial aneurysm</gtr:title><gtr:yearProtectionGranted>2011</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>A method for measuring free light chain immunoglobulins</gtr:description><gtr:grantRef>G0801681</gtr:grantRef><gtr:id>B8509468-C818-4F44-9D79-8535E866A2CF</gtr:id><gtr:impact>Development of a near patient test</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>Aaxy6dqgQtE</gtr:outcomeId><gtr:patentId>WO2010049672</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Free light chain assay</gtr:title><gtr:yearProtectionGranted>2010</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>The use of encapsulated alginates to prevent colorectal cancer</gtr:description><gtr:grantRef>G0801681</gtr:grantRef><gtr:id>3D8F7E3E-8EAB-48C8-8CC3-9BC71D2AF36E</gtr:id><gtr:impact>None</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>VHcQygbeJVD</gtr:outcomeId><gtr:patentId>WO2011051665</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>The use of alginates to prevent cancer</gtr:title><gtr:yearProtectionGranted>2011</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>a vaccine candidate for salmonella</gtr:description><gtr:grantRef>G0801681</gtr:grantRef><gtr:id>8433A326-909E-4BE2-9915-65A4E97FC13A</gtr:id><gtr:impact>None</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>LezJzxYfMgR</gtr:outcomeId><gtr:patentId>EP2324051</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Salmonella vaccine</gtr:title><gtr:yearProtectionGranted>2008</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>A composition for the improvement of gastrointestinal health and/or for the improvement of a gastrointestinal bacterial population</gtr:description><gtr:grantRef>G0801681</gtr:grantRef><gtr:id>31D2242E-5674-4550-AAE9-1BCE4B9BB5B0</gtr:id><gtr:impact>Further interactions with potential industry partners for lead academic</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>KDDmMWZBLia</gtr:outcomeId><gtr:patentId>WO2012146890</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Prebiotic agent</gtr:title><gtr:yearProtectionGranted>2012</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>The invention relates to the use of certain diarylethane derivatives in the treatment of certain medical conditions. In particular, it relates to the use of diarylethane derivatives in the treatment of medical conditions known to be mediated by the action of the 5a-reductase enzyme.</gtr:description><gtr:grantRef>G0801681</gtr:grantRef><gtr:id>52850B74-A5FC-4896-B5EE-2FE21114EAA5</gtr:id><gtr:impact>N/A</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>qgt1Yauaeiq</gtr:outcomeId><gtr:patentId>WO2012110768</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Therapeutic uses of diarylalkanes</gtr:title><gtr:yearProtectionGranted>2012</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>A method of identifying a modulator of the immune response system, comprising assaying for the effect of a compound on the internalisation and recycling of CTLA-4 in a cell, wherein an increase in cycling of CTLA-4 compared to a control without the compound indicates that the compound suppresses the immune response and a decrease in the cycling of CTLA-4 compared to a control without the compound, indicates that the compound increases the immune response. The cycling of CTLA-4 may be determined by monitoring CTLA-4 or monitoring uptake of a CTLA-4 label into a cell.</gtr:description><gtr:grantRef>G0801681</gtr:grantRef><gtr:id>C0A58489-10C1-44F0-A742-954BF3E79FF1</gtr:id><gtr:impact>Further industrial discussions to identify future collaborative opportunities for lead academic.</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>B4PKt3y9nnG</gtr:outcomeId><gtr:patentId>WO2012127240</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Immune Assay</gtr:title><gtr:yearProtectionGranted>2012</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>An agent for preventing or treating a condition characterised by the presence of unwanted cells, the agent comprising: (i) a targeting moiety that is capable of targeting to the unwanted cells; and (ii) a T cell antigen, wherein the T cell antigen can be released from the targeting moiety by selective cleavage of a cleavage site in the agent in the vicinity of the unwanted cells.</gtr:description><gtr:grantRef>G0801681</gtr:grantRef><gtr:id>2693F718-C27E-4DEB-B4FC-F09CA4E28A29</gtr:id><gtr:impact>Further discussions with industry representatives for lead academic to identify future funding opportunities</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>EcbexXBgX1h</gtr:outcomeId><gtr:patentId>WO2012123755</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Re-directed immunotherapy</gtr:title><gtr:yearProtectionGranted>2012</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>B44E06E2-4CBF-4E39-A0BC-7870270ACBDD</gtr:id><gtr:title>Exploring Inpatient Hospitalizations and Morbidity in Patients With Adrenal Insufficiency.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical endocrinology and metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b5d8ef8943d35a20e95fca492fd3713e"><gtr:id>b5d8ef8943d35a20e95fca492fd3713e</gtr:id><gtr:otherNames>Stewart PM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0021-972X</gtr:issn><gtr:outcomeId>5899ccccb7c184.28270689</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>26872429-8C10-4463-941F-6769EA77AA06</gtr:id><gtr:title>High throughput LC-MS/MS method for the simultaneous analysis of multiple vitamin D analytes in serum.</gtr:title><gtr:parentPublicationTitle>Journal of chromatography. B, Analytical technologies in the biomedical and life sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/179964427664d560060191a8a6c31cf4"><gtr:id>179964427664d560060191a8a6c31cf4</gtr:id><gtr:otherNames>Jenkinson C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1570-0232</gtr:issn><gtr:outcomeId>5899cc5ff28a72.05872234</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FFB24E18-7A64-4799-A420-DFDA97FD3074</gtr:id><gtr:title>11?-Hydroxysteroid dehydrogenase type 1 within muscle protects against the adverse effects of local inflammation.</gtr:title><gtr:parentPublicationTitle>The Journal of pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/88d98bf3954a69fc156c27af9fb0725e"><gtr:id>88d98bf3954a69fc156c27af9fb0725e</gtr:id><gtr:otherNames>Hardy RS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-3417</gtr:issn><gtr:outcomeId>5899ccce1275a6.73528981</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3DB7CDA2-050F-4573-A557-CEAA89A6B8A7</gtr:id><gtr:title>Glucocorticoids and 11?-HSD1 are major regulators of intramyocellular protein metabolism.</gtr:title><gtr:parentPublicationTitle>The Journal of endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/50266dbb5bd134a51e37cc9434e56cf3"><gtr:id>50266dbb5bd134a51e37cc9434e56cf3</gtr:id><gtr:otherNames>Morgan SA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-0795</gtr:issn><gtr:outcomeId>5899cccb289589.72720995</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F7C857B6-5775-40F8-A442-66A8DA7231D0</gtr:id><gtr:title>Acromegaly.</gtr:title><gtr:parentPublicationTitle>QJM : monthly journal of the Association of Physicians</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/01dc0ed26132145d0eddfb05f09f7965"><gtr:id>01dc0ed26132145d0eddfb05f09f7965</gtr:id><gtr:otherNames>Dineen R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1460-2393</gtr:issn><gtr:outcomeId>5899cc38528dc8.91468951</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>74DC5555-AF79-47B1-AC1A-DA0AEBB62FA6</gtr:id><gtr:title>Male 11?-HSD1 Knockout Mice Fed Trans-Fats and Fructose Are Not Protected From Metabolic Syndrome or Nonalcoholic Fatty Liver Disease.</gtr:title><gtr:parentPublicationTitle>Endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/74757ba33a4f5d12d4ab5eea50de0695"><gtr:id>74757ba33a4f5d12d4ab5eea50de0695</gtr:id><gtr:otherNames>Larner DP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0013-7227</gtr:issn><gtr:outcomeId>5899cccc346691.00551550</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>989B7CED-E224-49CF-BB50-EA55E9BE65EF</gtr:id><gtr:title>Immediate versus modified release hydrocortisone in mitotane-treated patients with adrenocortical cancer.</gtr:title><gtr:parentPublicationTitle>Clinical endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/015b14afa6b5b3668d14f53b709742c8"><gtr:id>015b14afa6b5b3668d14f53b709742c8</gtr:id><gtr:otherNames>Weigel M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0300-0664</gtr:issn><gtr:outcomeId>5899ccce911dd5.94872711</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B5115408-1217-4954-ABEF-128C81CBA6E3</gtr:id><gtr:title>SFRP2 Is Associated with Increased Adiposity and VEGF Expression.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6faad224b0d9f2591b7db726f3b40c7a"><gtr:id>6faad224b0d9f2591b7db726f3b40c7a</gtr:id><gtr:otherNames>Crowley RK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>5899cccd4ab794.53893970</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1A7D2763-E84B-4606-87D2-D8EA45673288</gtr:id><gtr:title>Mortality in patients with Cushing's disease more than 10 years after remission: a multicentre, multinational, retrospective cohort study.</gtr:title><gtr:parentPublicationTitle>The lancet. Diabetes &amp; endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3371bf5bd214349b10832ad888e2b5a7"><gtr:id>3371bf5bd214349b10832ad888e2b5a7</gtr:id><gtr:otherNames>Clayton RN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2213-8587</gtr:issn><gtr:outcomeId>5899cccbaf37b7.12024305</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0801681</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>F3822669-BB5A-4BB4-BAE0-DCB9DE36E092</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Generic Health Relevance</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>5191BE6E-A234-4D62-A4F3-B50DBAAE8217</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>4.5  Resources and infrastructure (detection)</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>A056411B-DD7A-4062-BE33-7849FBC9BFA7</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>5.9  Resources and infrastructure (development of treatments)</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>